Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is characterized by high levels of fibrosis, termed desmoplasia, which is thought to hamper the efficacy of therapeutics treating PDAC. Our primary focus was to evaluate differences in the extent of desmoplasia in primary tumors and metastatic lesions. As metastatic burden is a primary cause for mortality in PDAC, the extent of desmoplasia in metastases may help to determine whether desmoplasia targeting therapeutics will benefit patients with late-stage, metastatic disease. Experimental Design: We sought to assess desmoplasia in metastatic lesions of PDAC and compare it with that of primary tumors. Fifty-three patients' primaries and 57 patients' metastases were stained using IHC staining techniques. Results: We observed a significant negative correlation between patient survival and extracellular matrix deposition in primary tumors. Kaplan–Meier curves for collagen I showed median survival of 14.6 months in low collagen patients, and 6.4 months in high-level patients (log rank, P < 0.05). Low-level hyaluronan patients displayed median survival times of 24.3 months as compared with 9.3 months in high-level patients (log rank, P < 0.05). Our analysis also indicated that extracellular matrix components, such as collagen and hyaluronan, are found in high levels in both primary tumors and metastatic lesions. The difference in the level of desmoplasia between primary tumors and metastatic lesions was not statistically significant. Conclusions: Our results suggest that both primary tumors and metastases of PDAC have highly fibrotic stroma. Thus, stromal targeting agents have the potential to benefit PDAC patients, even those with metastatic disease. Clin Cancer Res; 21(15); 3561–8. ©2015 AACR. See related commentary by Olive, p. 3366

[1]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[2]  Karen Margolis,et al.  Disclosure of Potential Conflicts of Interest , 2014 .

[3]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[4]  C. Pilarsky,et al.  CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer , 2013, Proceedings of the National Academy of Sciences.

[5]  R. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Derek S. Chan,et al.  Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer , 2012, Gut.

[7]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[8]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[9]  Triantafyllos Stylianopoulos,et al.  Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors , 2012, Proceedings of the National Academy of Sciences.

[10]  H. Shepard,et al.  Effective targeting of the tumor microenvironment for cancer therapy. , 2012, Anticancer research.

[11]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[12]  Z. Naito,et al.  Report on Experiments and Clinical Cases ― Clinicopathological Features of 30 Autopsy Cases of Pancreatic Carcinoma , 2012 .

[13]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Hostetter,et al.  Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. , 2011, Cancer discovery.

[15]  Dai Fukumura,et al.  Malignant cells facilitate lung metastasis by bringing their own soil , 2010, Proceedings of the National Academy of Sciences.

[16]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[17]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[18]  Ajit Varki,et al.  Molecular basis of metastasis. , 2009, The New England journal of medicine.

[19]  Helmut Friess,et al.  The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  A. Verkman,et al.  Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Jason C. Ho,et al.  The Integrin-Extracellular Matrix Axis in Pancreatic Cancer , 2007, Pancreas.

[22]  M. Choti,et al.  Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis , 2007, Annals of Surgical Oncology.

[23]  D. V. Von Hoff,et al.  Tumor-stroma interactions in pancreatic ductal adenocarcinoma , 2007, Molecular Cancer Therapeutics.

[24]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[25]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[26]  R. Bell,et al.  Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. , 2002, Surgery.

[27]  E. Castaños-Vélez,et al.  Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. , 2001, Hepato-gastroenterology.

[28]  A. Theocharis,et al.  Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. , 2000, Biochimica et biophysica acta.

[29]  R. Jain,et al.  Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.

[30]  V. Kosma,et al.  Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. , 2000, The American journal of pathology.

[31]  V. Kosma,et al.  High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. , 2000, Cancer research.

[32]  M. Korsten,et al.  Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis , 1999, Gut.

[33]  V. Kosma,et al.  Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate , 1999, British Journal of Cancer.

[34]  B. le Bail,et al.  Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. , 1999, Journal of hepatology.

[35]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[36]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[37]  A. Reilley,et al.  An investigation of the cause of death from cancer , 1980, Journal of surgical oncology.

[38]  J. A. Robinson,et al.  Endotoxin, prekallikrein, complement and systemic vascular resistance. Sequential measurements in man. , 1975, The American journal of medicine.

[39]  J. Ambrus,et al.  Causes of death in cancer patients. , 1975, Journal of medicine.